Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Brand profile · Biotechnology Research
BCAL Diagnostics is a Biotechnology Research brand in Sydney, New South Wales. Publicly held, at bcaldiagnostics.com. It holds one address on record, all in Australia. It employs 20 people, on the record. One Australian registration (ABN) is a candidate match. Its latest round on record is Post IPO equity, US$10.5M. It is listed alongside eight similar brands, mostly in Biotechnology Research.
ABN51142051223
| BCAL DIAGNOSTICS LIMITED | ABN 51142051223 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
BCAL Diagnostics is an Australian-owned, ASX listed, biotechnology company. Since its establishment in 2010, BCAL Diagnostics has been striving to help identify health issues in women that is safe, accessible and cost effective.
| Countries | 1 |
|---|
All codes: AU
| Rounds | 1 |
|---|---|
| Axis | 2010 to 2026 |
| Post IPO equity · 3 Jul 2024 | US$ 10.5M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Hiring, headcount and registry-change signals, streamed to members.
Registry-filed capital and financial indicators, standardised by TheGrid.
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
One New South Wales entity on the ABR: BCAL DIAGNOSTICS LIMITED (ABN 51 142 051 223), medium confidence.
20 counted staff profiles at January 2026, inside the self-reported 11–50 band.
One address on record, Australia only.
One round. Latest 3 July 2024: post IPO equity, US$10,500,000.
15 profiles list BCAL Diagnostics as a peer — 90th percentile in Biotechnology Research. It lists ten peers of its own. Island Pharmaceuticals and Sydney Breast Clinic list it back.